Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Southwest Oncology Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00058448 |
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have locally advanced or metastatic penile cancer.
Condition | Intervention | Phase |
---|---|---|
Penile Cancer |
Drug: docetaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Study Of Weekly Docetaxel In Patients With Advanced Epidermoid Carcinoma Of The Penis |
Study Start Date: | October 2004 |
OBJECTIVES:
OUTLINE: Patients receive docetaxel IV over 15-30 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 3-5.8 years.
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed epidermoid carcinoma of the penis
Measurable disease
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
SGOT no greater than 2.5 times ULN
Alkaline phosphatase no greater than 4 times ULN
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Study Chair: | Tomasz M. Beer, MD | Oregon Health and Science University Cancer Institute |
Study Chair: | Roland T. Skeel, MD | Medical University of Ohio Cancer Center |
Study ID Numbers: | CDR0000297621, SWOG-S0224, ECOG-S0224 |
Study First Received: | April 7, 2003 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00058448 |
Health Authority: | United States: Federal Government |
stage II penile cancer stage III penile cancer stage IV penile cancer |
Docetaxel Epidermoid carcinoma Genital Neoplasms, Male Squamous cell carcinoma Carcinoma, squamous cell |
Urogenital Neoplasms Penile Neoplasms Genital Diseases, Male Carcinoma, Squamous Cell Carcinoma |
Neoplasms Neoplasms by Site Antineoplastic Agents |
Therapeutic Uses Penile Diseases Pharmacologic Actions |